S
Spear Bio
Offers opportunities for better detections with less invasive biospecimen collection
About Spear Bio
Spear Bio is a biotechnology startup that specializes in the detection of low abundance biomarkers, which are indicators of disease in the body. Their technology is particularly adept at identifying these biomarkers in the early stages of disease, with the ability to detect even single-digit counts of proteins per sample. This high level of precision is achieved through their proprietary 2-factor authentication detection technology.
The company's technology requires sub-microliter samples, which allows for minimally invasive sample collection. This makes it easier to conduct more tests from smaller samples, enabling broader scale research or screening, particularly in asymptomatic subjects.
Spear Bio's business model is based on providing this technology to labs, which can then use it to scale up testing for large groups of subjects. The technology is compatible with any non-proprietary qPCR instruments, meaning it can be easily automated on open liquid handling platforms. This flexibility allows labs to rapidly scale testing without needing to invest in proprietary instruments.
One of the company's key products is the NAB-Sure™ SARS CoV-2 Kit, which simplifies testing for SARS-CoV-2 neutralizing antibodies. The kit uses real-time PCR systems to produce both qualitative and quantitative measurements, combining high accuracy with unparalleled sensitivity.
In summary, Spear Bio operates in the biotechnology market, serving clients such as research labs and healthcare providers. Their business model is based on providing highly sensitive and precise biomarker detection technology, which can be easily integrated into existing lab setups. They generate revenue by selling their technology and testing kits to these clients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Woburn, United States
- Employees
- 54
- Open positions
- 7
- Dealroom signal
- 88.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2024 | $45M | $180M | Maverick Ventures · CDH Investments · Foresite Capital · Bio-Techne | ↗ |
| SEEDOther financing | Nov 2023 | $2.7M | $15M | CDH Investments · Yonghua Capital · Sequoia · Maverick Ventures | ↗ |
Growth signals
Latest recorded traffic for Spear Bio is 6.1K monthly website visits, up 90.6% over the last three months. Spear Bio's team grew 10.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
CDH Investments
Yonghua Capital
Sequoia
Maverick Ventures
Series A2 investors entered at this stage
Foresite Capital
Bio-Techne
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spear Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spear Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







